| Cas No.: | 59263-76-2 |
| Chemical Name: | Meptazinol hydrochloride |
| Synonyms: | Meptazinol hydrochloride;3-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride;Meptazinol HCl;Meptazinol Hydrochlo;3-(3-ethyl-1-methylazepan-3-yl)phenol,hydrochloride;IL-22811 hydrochloride;WY-22811 hydrochloride;3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)-phenol hydrochloride;Meptazinol (hydrochloride);Meptazinol hydrochloride [USAN];IL 22811;WY 22811;3-(3-ethyl-1-methylazepan-3-yl)phenol hydrochloride;m-(3-Ethyl-1-methyl-hexahydro-1H-azepin-3-yl)phenol hydrochloride;m-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochlo |
| SMILES: | Cl.CCC1(CN(C)CCCC1)C2=CC(O)=CC=C2 |
| Formula: | C15H24ClNO |
| M.Wt: | 269.8102 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Meptazinol Hcl(WY-22811 Hcl) is a unique centrally active opioid analgesic. |
| In Vivo: | in vivo: Given at equianalgesic doses, morphine (3.5 mg/kg i.v.) significantly lowers the pO2 over 20 mm Hg and raises the pCO2 over 10 mm Hg as measured in arterial blood samples, whereas meptazinol (10 mg/kg i.v.) has no significant effects on either. The group receiving meptazinol demonstrated no cardiovascular changes although bispectral index dropped by an additional 19% when compared to 1 min after barbiturate injection . Rapid and significant levels of MEP in plasma and CSF can be achieved after nasal administration whereas the oral administration resulted in considerably lower drug concentrations. |
| In Vitro: | in vitro: Meptazinol inhibits a portion of 3H-labeled opiate and opioid peptide binding quite potently, with IC50 value under 1 nM. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|
| 2018-0101 |
|